INCYTE CORPORATION
About INCYTE CORPORATION
Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics for patients with unmet medical needs in oncology and inflammation & autoimmunity. It has established a portfolio of first-in-class medicines and maintains operations in North America, Europe, and Asia. Headquartered in Wilmington, Delaware, the company is publicly traded on NASDAQ under the symbol INCY.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Publicly traded on NASDAQ (INCY) with 2024 revenue of $4.24 billion.
- Operates a pipeline focused on oncology and inflammation & autoimmunity.
- Headquartered in Wilmington, DE with global operations across North America, Europe and Asia.
- Equity inducement grant of $297,779.82 issued under Rule 144 to new EVP and General Counsel.
Ask StreetZero about INCYTE CORPORATION
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account